Burdensome Research Procedures in Trials: Why Less Is More
- PMID: 28376159
- PMCID: PMC5756064
- DOI: 10.1093/jnci/djw315
Burdensome Research Procedures in Trials: Why Less Is More
Abstract
A large volume of trials involve invasive, nontherapeutic research procedures, like organ biopsy or sham surgeries, that can pose risks comparable with the experimental treatment itself but that have no direct benefit for volunteers. Though such procedures can enhance the value of clinical investigations, recent studies suggest that many studies involving invasive, nontherapeutic research procedures are not well planned and reported; some studies suggest that their results are often not utilized in the planning of new investigations. This commentary offers recommendations for how investigators, sponsors, and ethics committees might improve evaluation and implementation of studies involving invasive nontherapeutic procedures. We conclude by urging more demanding scientific standards for the rationale, design, and reporting of burdensome, nontherapeutic research procedures-particularly where they involve risk of serious complications.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Comment in
-
Tissue Acquisition in Clinical Trials-Essential for Progress.J Natl Cancer Inst. 2017 Apr 1;109(4):djx003. doi: 10.1093/jnci/djx003. J Natl Cancer Inst. 2017. PMID: 28376161 Free PMC article. No abstract available.
Similar articles
-
Survey of users of TOPS, an internet-based system to prevent healthy subjects from over-volunteering for clinical trials.Eur J Clin Pharmacol. 2013 Oct;69(10):1757-60. doi: 10.1007/s00228-013-1534-4. Epub 2013 Jun 7. Eur J Clin Pharmacol. 2013. PMID: 23743779
-
Clinical research with healthy volunteers: an ethical framework.J Investig Med. 2003 Feb;51 Suppl 1:S2-5. J Investig Med. 2003. PMID: 12664947
-
Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit.JAMA. 2005 Aug 17;294(7):826-32. doi: 10.1001/jama.294.7.826. JAMA. 2005. PMID: 16106008
-
Demarcating research and treatment: a systematic approach for the analysis of the ethics of clinical research.Clin Res. 1992 Dec;40(4):653-60. Clin Res. 1992. PMID: 1486732 Review. No abstract available.
-
Lessons for HIV from Tuskegee.J HIV Ther. 2004 Sep;9(3):50-2. J HIV Ther. 2004. PMID: 15534560 Review.
Cited by
-
Understanding factors contributing to participant satisfaction in stroke walking recovery clinical trials.Contemp Clin Trials Commun. 2022 Jun 11;28:100945. doi: 10.1016/j.conctc.2022.100945. eCollection 2022 Aug. Contemp Clin Trials Commun. 2022. PMID: 35754974 Free PMC article.
-
Implications of Research Biopsies in Clinical Trials.Oncologist. 2021 Dec;26(12):994-996. doi: 10.1002/onco.13948. Epub 2021 Aug 31. Oncologist. 2021. PMID: 34418217 Free PMC article.
-
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.Breast Cancer Res Treat. 2022 Jul;194(1):171-178. doi: 10.1007/s10549-022-06611-6. Epub 2022 May 11. Breast Cancer Res Treat. 2022. PMID: 35538268 Free PMC article.
-
Risk Assessment of Medical Study Procedures in the Documents Submitted to a Research Ethics Committee.J Empir Res Hum Res Ethics. 2020 Dec;15(5):396-406. doi: 10.1177/1556264620903563. Epub 2020 Feb 8. J Empir Res Hum Res Ethics. 2020. PMID: 32036724 Free PMC article.
-
Therapeutic Misconception about Research Procedures: Does a Simple Information Chart Improve Understanding?Ethics Hum Res. 2022 Mar;44(2):18-25. doi: 10.1002/eahr.500120. Ethics Hum Res. 2022. PMID: 35218599 Free PMC article.
References
-
- Goulart BH, Clark JW, Pien HH, et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007;13(22 Pt 1):6719–6726. - PubMed
-
- Wong HH, Barton C, Acton G, et al. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience. Eur J Cancer. 2016;66:9–16. - PubMed
-
- U.S. Food and Drug Administration. Hematology/oncology (cancer) approvals and safety notifications. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm. Accessed June 17, 2016.
-
- Yap TA, Sandhu SK, Workman P, et al. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010;107:514–523. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical